By Fineline Cube 
China-based Youjia (Hangzhou) Biomedical Technology Co., Ltd. has signed a licensing agreement with compatriot firm Livzon Pharmaceutical Group Inc. (HKG: 1513), marking a significant step in the global development of a novel small interfering RNA (siRNA) product for the treatment of metabolic diseases.
Terms of the Licensing Agreement
Under the agreement, Livzon Pharmaceutical Group Inc. will secure exclusive global development, manufacturing, and commercialization rights to Youjia Bio’s Category 1 chemical drug. This siRNA product is designed to address metabolic diseases, offering a new therapeutic approach in the field. In return for these rights, Livzon Pharma will pay Youjia Bio an undisclosed amount, which includes an upfront payment, development milestone payments, and sales commissions.
Potential Impact of the siRNA Product
The drug, characterized by its long-lasting efficacy, low toxicity, and low frequency of administration, has demonstrated good safety in pre-clinical studies. These attributes suggest that the siRNA product could provide a more effective and safer treatment option for patients with metabolic diseases, potentially transforming the treatment landscape.-Fineline Info & Tech